246 related articles for article (PubMed ID: 15827098)
1. Adrenal ganglioneuromas in children with multiple endocrine neoplasia type 2: a report of two cases.
Lora MS; Waguespack SG; Moley JF; Walvoord EC
J Clin Endocrinol Metab; 2005 Jul; 90(7):4383-7. PubMed ID: 15827098
[TBL] [Abstract][Full Text] [Related]
2. Ganglioneuromas and renal anomalies are induced by activated RET(MEN2B) in transgenic mice.
Sweetser DA; Froelick GJ; Matsumoto AM; Kafer KE; Marck B; Palmiter RD; Kapur RP
Oncogene; 1999 Jan; 18(4):877-86. PubMed ID: 10023663
[TBL] [Abstract][Full Text] [Related]
3. C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B.
Smith-Hicks CL; Sizer KC; Powers JF; Tischler AS; Costantini F
EMBO J; 2000 Feb; 19(4):612-22. PubMed ID: 10675330
[TBL] [Abstract][Full Text] [Related]
4. Ret protein expression in adrenal medullary hyperplasia and pheochromocytoma.
Powers JF; Brachold JM; Tischler AS
Endocr Pathol; 2003; 14(4):351-61. PubMed ID: 14739491
[TBL] [Abstract][Full Text] [Related]
5. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B.
Zhou Y; Zhao Y; Cui B; Gu L; Zhu S; Li J; Liu J; Yin M; Zhao T; Yin Z; Yu C; Chen C; Wang L; Xiao B; Hong J; Zhang Y; Tang Z; Wang S; Li X; Ning G
Clin Endocrinol (Oxf); 2007 Oct; 67(4):570-6. PubMed ID: 17573899
[TBL] [Abstract][Full Text] [Related]
6. [The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].
Ito T; Shirahama S; Ogura K; Yamamoto S; Takami H
Nihon Rinsho; 2004 May; 62(5):883-8. PubMed ID: 15148813
[TBL] [Abstract][Full Text] [Related]
7. RET(Men2B)-transgene produces sympathoadrenal tumors but does not prevent intestinal aganglionosis in gdnf-/- or gfr alpha-1(-/-) mice.
Rajan I; Gestblom C; Kapur RP
Pediatr Dev Pathol; 2001; 4(5):446-53. PubMed ID: 11779046
[TBL] [Abstract][Full Text] [Related]
8. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase.
Marshall GM; Peaston AE; Hocker JE; Smith SA; Hansford LM; Tobias V; Norris MD; Haber M; Smith DP; Lorenzo MJ; Ponder BA; Hancock JF
Cancer Res; 1997 Dec; 57(23):5399-405. PubMed ID: 9393766
[TBL] [Abstract][Full Text] [Related]
9. Genetic testing in multiple endocrine neoplasia and related syndromes.
Calender A
Forum (Genova); 1998; 8(2):146-59. PubMed ID: 9666051
[TBL] [Abstract][Full Text] [Related]
10. [Neural crest and multiple endocrinopathies].
Pasini A; Michiels FM; Chappuis-Flament S; Geneste O; Rossel M; Fournier L; Feunteun J; Lenoir G; Schuffenecker I; Billaud M
C R Seances Soc Biol Fil; 1996; 190(5-6):557-67. PubMed ID: 9074721
[TBL] [Abstract][Full Text] [Related]
11. Composite paraganglioma-ganglioneuroma concomitant with adrenal metastasis of medullary thyroid carcinoma in a patient with multiple endocrine neoplasia type 2B: A case report.
Yamasaki M; Sato Y; Nomura T; Sato F; Uchino S; Mimata H
Asian J Endosc Surg; 2017 Feb; 10(1):66-69. PubMed ID: 27704704
[TBL] [Abstract][Full Text] [Related]
12. Clinical manifestations of familial medullary thyroid carcinoma.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):348-50. PubMed ID: 15271414
[TBL] [Abstract][Full Text] [Related]
13. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
14. [Multiple endocrine neoplasia type 2].
Niccoli-Sire P; Conte-Devolx B
Ann Endocrinol (Paris); 2007 Oct; 68(5):317-24. PubMed ID: 17626779
[TBL] [Abstract][Full Text] [Related]
15. Multiple endocrine neoplasia type 2.
Lodish M
Front Horm Res; 2013; 41():16-29. PubMed ID: 23652668
[TBL] [Abstract][Full Text] [Related]
16. A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells.
Califano D; D'Alessio A; Colucci-D'Amato GL; De Vita G; Monaco C; Santelli G; Di Fiore PP; Vecchio G; Fusco A; Santoro M; de Franciscis V
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7933-7. PubMed ID: 8755580
[TBL] [Abstract][Full Text] [Related]
17. Pediatric head and neck manifestations associated with multiple endocrine neoplasia syndromes.
Jellins T; Hill M; Prager JD; Francom CR; Chan CM; Schneider KW; Sharma A; Herrmann BW
Int J Pediatr Otorhinolaryngol; 2023 Oct; 173():111703. PubMed ID: 37604101
[TBL] [Abstract][Full Text] [Related]
18. MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives.
Amodru V; Taieb D; Guerin C; Romanet P; Paladino N; Brue T; Cuny T; Barlier A; Sebag F; Castinetti F
Endocrine; 2020 Sep; 69(3):496-503. PubMed ID: 32388798
[TBL] [Abstract][Full Text] [Related]
19. The Reality of Multiple Endocrine Neoplasia Type 2B Diagnosis: Awareness of Unique Physical Appearance Is Important.
Nagaoka R; Sugitani I; Sanada M; Jikuzono T; Okamura R; Igarashi T; Akasu H; Shimizu K
J Nippon Med Sch; 2018; 85(3):178-182. PubMed ID: 30135345
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
